B-cell depletion immunotherapy in pemphigus: Effects on cellular and humoral immune responses

Journal of Investigative Dermatology

Volumn 128, Issue 12, 2008, Pages 2859-2869

  Mouquet, Hugo ^a,b   Musette, Philippe ^a,b,c,h   Gougeon, Marie Lyse ^d   Jacquot, Serge ^a,b   Lemercier, Brigitte ^d   Lim, Annick ^d   Gilbert, Danièle ^a,b   Dutot, Ingrid ^a,b   Roujeau, Jean C ^e   D'Incan, Michel ^f   Bedane, Christophe ^g   Tron, François ^a,b   Joly, Pascal ^a,b,c  

^a faculté mixte de médecine et de pharmacie de Rouen   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d INSTITUT PASTEUR   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^g LIMOGES UNIVERSITY HOSPITAL   (France)

^h HÔPITAL CHARLES NICOLLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIBODY; CD20 ANTIBODY; CD24 ANTIGEN; CD38 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PNEUMOCOCCUS POLYSACCHARIDE; RITUXIMAB; TETANUS TOXOID;

ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; MALE; MULTIPLE CYCLE TREATMENT; PEMPHIGUS; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, CD19; ANTIGENS, CD20; ANTIGENS, CD24; ANTIGENS, CD38; B-LYMPHOCYTES; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOTHERAPY; PEMPHIGUS; PHENOTYPE; POLYSACCHARIDES;

EID: 57349155546     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2008.178     Document Type: Article

References (62)

1. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR (2006) Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355:1772-9
2. Amagai M, Hashimoto T, Green KJ, Shimizu N, Nishikawa T (1995) Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol 104:895-901
3. Amagai M, Hashimoto T, Shimizu N, Nishikawa T (1994) Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 94:59-67
4. Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR (1992) Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 90:919-26
5. Amagai M, Komai A, Hashimoto T, Shirakata Y, Hashimoto K, Yamada T et al. (1999a) Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 140:351-7
6. Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T (1999b) The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 40:167-70
7. Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E et al. (2007) B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 122:139-45
8. Arin MJ, Engert A, Krieg T, Hunzelmann N (2005) Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 153:620-5
9. Ballet JJ, Sulcebe G, Couderc LJ, Danon F, Rabian C, Lathrop M et al. (1987) Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy. Clin Exp Immunol 68:479-87
10. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M et al. (2003) Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48:2146-54
11. Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA et al. (2006) B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 54:3612-22
12. Carsetti R, Rosado MM, Wardmann H (2004) Peripheral development of B cells in mouse and man. Immunol Rev 197:179-91
13. Cheng SW, Kobayashi M, Kinoshita-Kuroda K, Tanikawa A, Amagai M, Nishikawa T (2002) Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 147:261-5
14. Cheson BD (2002) CHOP plus rituximab - balancing facts and opinion. N Engl J Med 346:280-2
15. Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P (2007) Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol 143:1033-8
16. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S et al. (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125:232-9
17. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA (2006) Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 180:63-70
18. Cuss AK, Avery DT, Cannons JL, Yu LJ, Nichols KE, Shaw PJ et al. (2006) Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity. J Immunol 176:1506-16
19. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G (2002) Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 46:2029-33
20. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Hertl M (2006) Treatment with rituximab (anti-CD20) affects both autoreactive T and B lymphocytes in pemphigus vulgaris. J Invest Dermatol 126:22A
21. Giagounidis AA, Anhuf J, Schneider P, Germing U, Sohngen D, Quabeck K et al. (2002) Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 69:95-100
22. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L et al. (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174:817-26
23. Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM (2001) The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol 144:775-80
24. Hertl M, Eming R, Veldman C (2006) T cell control in autoimmune bullous skin disorders. J Clin Invest 116:1159-66
25. Hoyer BF, Moser K, Hauser AE, Peddinghaus A, Voigt C, Eilat D et al. (2004) Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 199:1577-84
26. Ishii K, Amagai M, Hall RP, Hashimoto T, Takayanagi A, Gamou S et al. (1997) Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 159:2010-7
27. Ishii K, Harada R, Matsuo I, Shirakata Y, Hashimoto K, Amagai M (2005) In vitro keratinocyte dissociation assay for evaluation of the pathogenicity of anti-desmoglein 3 IgG autoantibodies in pemphigus vulgaris. J Invest Dermatol 124:939-46
28. Joly P, D'Incan M, Musette P (2007a) Rituximab for pemphigus vulgaris. N Engl J Med 356:521; author reply 521-522
29. Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S et al. (2007b) A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 357:545-52
30. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54:613-20
31. Leandro MJ, Edwards JC, Cambridge G (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61:883-8
32. Lever WF (1979) Pemphigus and pemphigoid. A review of the advances made since 1964. J Am Acad Dermatol 1:2-31
33. Levine TD (2005) Rituximab in the treatment of dermatomyositis: an openlabel pilot study. Arthritis Rheum 52:601-7
34. Li N, Aoki V, Hans-Filho G, Rivitti EA, Diaz LA (2003) The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem). J Exp Med 197:1501-10
35. Lim A, Lemercier B, Wertz X, Pottier SL, Huetz F, Kourilsky P (2008) Many human peripheral VH5-expressing IgM+ B cells display a unique heavychain rearrangement. Int Immunol 20:105-16
36. Looney RJ, Anolik J, Sanz I (2005) Treatment of SLE with anti-CD20 monoclonal antibody. Curr Dir Autoimmun 8:193-205
37. Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR (1999) Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 103:461-8
38. Marie-Cardine A, Divay F, Dutot I, Green A, Perdrix A, Boyer O et al. (2008) Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation. Clin Immunol 127:14-25
39. Martel P, Joly P (2001) Pemphigus: autoimmune diseases of keratinocyte's adhesion molecules. Clin Dermatol 19:662-74
40. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-33
41. Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L et al. (2008) Consensus statement on definitions of disease, endpoints, and therapeutic response for pemphigus. J Am Acad Dermatol 2008;58:1043-6
42. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR et al. (2000) Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 165:5970-9
43. Pannetier C, Cochet M, Darche S, Casrouge A, Zoller M, Kourilsky P (1993) The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA 90:4319-23
44. Payne AS, Ishii K, Kacir S, Lin C, Li H, Hanakawa Y et al. (2005) Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. J Clin Invest 115:888-99
45. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM et al. (1999) Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10:655-61
46. Qian Y, Diaz LA, Ye J, Clarke SH (2007) Dissecting the anti-desmoglein autoreactive B cell repertoire in pemphigus vulgaris patients. J Immunol 178:5982-90
47. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T et al. (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev 6:741-50
48. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-45
49. Riley JK, Sliwkowski MX (2000) CD20: a gene in search of a function. Semin Oncol 27:17-24
50. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP (2006) Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54:2377-86
51. Roscoe JT, Diaz L, Sampaio SA, Castro RM, Labib RS, Takahashi Y et al. (1985) Brazilian pemphigus foliaceus autoantibodies are pathogenic to BALB/c mice by passive transfer. J Invest Dermatol 85:538-41
52. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101:3818-26
53. Sekiguchi M, Futei Y, Fujii Y, Iwasaki T, Nishikawa T, Amagai M (2001) Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins. J Immunol 167:5439-48
54. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE (2005) Identification and characterization of circulating human transitional B cells. Blood 105:4390-8
55. Specks U, Fervenza FC, McDonald TJ, Hogan MC (2001) Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44:2836-40
56. Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N et al. (2007) Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110:2924-30
57. Stasi R, Brunetti M, Stipa E, Amadori S (2004) Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 103:4424-8
58. Stasi R, Pagano A, Stipa E, Amadori S (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952-7
59. Sutter JA, Kwan-Morley J, Dunham J, Du YZ, Kamoun M, Albert D et al. (2008) A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): Factors associated with B lymphocyte recovery. Clin Immunol 126:282-90
60. Tsunoda K, Ota T, Aoki M, Yamada T, Nagai T, Nakagawa T et al. (2003) Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. J Immunol 170:2170-8
61. Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R et al. (2007) Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 122:62-74
62. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P et al. (2003) Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101:3857-61